Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Roivant Sciences raises $1.1bn to support new subsidiaries

Executive Summary

Roivant Sciences GMBH raised $1.1bn from lead investor SoftBank Vision Fund (the investment arm of Japanese tech giant SoftBank Group International) and additional returning backers including Dexxon. The funding, which is the largest private biopharma round to date, will support creation of new subsidiaries. Roivant's portfolio of drug development firms already includes Axovant (neurology), Dermavant (dermatology), Urovant (urology), Myovant (endrocrine diseases and women's health), and Enzyvant (rare diseases). It just announced a new division Datavant, which is the first Roivant company to operate outside of the drug development arena and instead focus on data analysis in clinical trials.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies